Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986414 + BMS-986413
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
BMS-986414 + BMS-986413 is a combination of two fully human monoclonal antibodies developed for the treatment of COVID-19. Both antibodies are recombinant IgG1κ and λ isotypes derived from individuals who recovered from COVID-19. They bind to non-overlapping sites on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and have been Fc-modified to extend their half-lives in humans. The combination was designed to improve efficacy against multiple variants and reduce resistance by targeting different epitopes on the virus. In clinical trials, subcutaneous administration was safe but did not show significant efficacy in treating mild-to-moderate COVID-19 in outpatients at low risk for progression[1][2][4][6].
- Other names
- C135/C144 antibody combination
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on BMS-986414 + BMS-986413.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986414 + BMS-986413.